PermeaDerm
Commercial- Indications
- Diabetic foot ulcer, Burns, Acute wounds, Chronic wounds
Company intelligence / Profile preview
Stedical Scientific’s lead product PermeaDerm® is a next-generation biosynthetic wound matrix with FDA 510(k) clearance. It is commercialized in at least ten countries for various acute and chronic wound indications. The platform allows variable porosity to tailor treatment to individual patient needs. Clinical use has demonstrated safety and efficacy for burns and chronic wounds.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Stedical Scientific.